share_log

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer Taubert Jennifer L

SEC announcement ·  Feb 21 07:00
Summary by Futu AI
Jennifer L. Taubert, EVP of Worldwide Commercialization, Innovative Medicine at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value, were not disclosed in the announcement. The action type and status of the transaction were also not provided. The report does not include information on the number of shares held by Taubert after the transaction.
Jennifer L. Taubert, EVP of Worldwide Commercialization, Innovative Medicine at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and total value, were not disclosed in the announcement. The action type and status of the transaction were also not provided. The report does not include information on the number of shares held by Taubert after the transaction.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.